从五洲医疗十大流通股东角度 截至发稿，孔宪政累计任职时间4年298天，现任基金资产总规模46.07亿元，任职期间最佳基金回报 77.68%， 任职期间最差基金回报-16.74%。 王海畅累计任职时间3年60天，现任基金资产总规模25.29亿元，任职期间最佳基金回报65.18%， 任职 期间最差基金回报-18.8%。 数据显示，诺安基金旗下1只基金位居五洲医疗十大流通股东。诺安多策略混合A（320016）二季度增 持18.16万股，持有股数32.79万股，占流通股的比例为1.78%。根据测算，今日浮盈赚取约78.37万元。 诺安多策略混合A（320016）成立日期2011年8月9日，最新规模13.99亿。今年以来收益59.64%，同类 排名541/8172；近一年收益124.24%，同类排名257/7980；成立以来收益208.1%。 诺安多策略混合A（320016）基金经理为孔宪政、王海畅。 9月19日，五洲医疗涨5.21%，截至发稿，报48.25元/股，成交6018.34万元，换手率1.91%，总市值32.81 亿元。 资料显示，安徽宏宇五洲医疗器械股份有限公司位于安徽省安庆市太湖县经济开发区观音路2号，成 ...

Group 1: Company Development Plans - The company focuses on the field of single-use sterile infusion medical consumables, including innovations in syringes, infusion and blood transfusion devices, and medical puncture needles [1][2] - The company aims to deepen technological innovation and expand market channels to establish a solid foundation for high-quality and sustainable development [1][2] Group 2: Investor Engagement - The investor relations activity was conducted via an online platform on September 15, 2025, from 14:00 to 17:00 [1] - The company expressed gratitude for investor support and emphasized the importance of referring to official disclosures for significant company matters [2]

Company Overview - Wuzhou Medical, established on April 15, 2011, is located in Taihu County, Anqing City, Anhui Province, and was listed on July 5, 2022 [1] - The company specializes in the research, production, and sales of disposable sterile infusion medical devices and other related medical supplies, primarily using an "ODM + integrated supply" model to meet the one-stop procurement needs of foreign medical device brand companies [1] - The main revenue composition includes: syringes 41.29%, medical puncture needles 25.51%, infusion and blood transfusion devices 20.92%, and others 12.28% [1] Stock Performance - On September 12, Wuzhou Medical's stock rose by 5.24%, reaching a price of 48.64 CNY per share, with a trading volume of 56.6895 million CNY and a turnover rate of 1.76%, resulting in a total market capitalization of 3.308 billion CNY [1] Shareholder Information - Noan Fund's Noan Multi-Strategy Mixed A (320016) fund is among the top ten circulating shareholders of Wuzhou Medical, having increased its holdings by 181,600 shares in the second quarter, totaling 327,900 shares, which represents 1.78% of the circulating shares [2] - The fund has achieved a year-to-date return of 61.81%, ranking 429 out of 8,174 in its category, and a one-year return of 121.96%, ranking 230 out of 7,981 [2]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Wuzhou Medical, which has a high PE ratio compared to its industry peers [1][2] - Wuzhou Medical's closing price on August 25 was 43.4 yuan, with a PE ratio of 102.77 and a total market capitalization of 2.951 billion yuan [1] - The company operates in the medical device sector, focusing on the research, manufacturing, and sales of disposable sterile infusion medical devices, with a product portfolio that includes syringes and infusion devices [1] Group 2 - As of the 2025 semi-annual report, Wuzhou Medical reported revenue of 217 million yuan, a slight decrease of 2.26% year-on-year, and a net profit of 10.5151 million yuan, reflecting a significant decline of 51.69% year-on-year [1] - The company's gross profit margin stands at 14.33%, indicating challenges in maintaining profitability [1] - In terms of institutional holdings, only two institutions hold shares in Wuzhou Medical, with a total of 478,600 shares valued at 1.4 million yuan [1]

Company Overview - Wuzhou Medical closed at 42.22 yuan, up 1.96%, with a rolling PE ratio of 99.97 times and a total market value of 2.871 billion yuan [1] - The company ranks 105th in the medical device industry, which has an average PE ratio of 56.95 times and a median of 40.49 times [1] Shareholder Information - As of July 31, 2025, Wuzhou Medical had 7,255 shareholders, an increase of 848 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Operations - Anhui Hongyu Wuzhou Medical Device Co., Ltd. specializes in the R&D, manufacturing, and sales of disposable sterile infusion medical devices, along with other diagnostic and nursing supplies [1] - The main products include syringes, infusion and blood transfusion devices, medical puncture needles, and other diagnostic and clinical care products [1] - The company holds 46 medical device product registration and filing certificates as of the reporting period [1] Financial Performance - In the latest semi-annual report for 2025, the company achieved operating revenue of 217 million yuan, a decrease of 2.26% year-on-year, and a net profit of 10.5151 million yuan, down 51.69% year-on-year, with a gross sales margin of 14.33% [1]

五洲医疗收盘上涨3.41%，滚动市盈率45.71倍，总 市值18.54亿元 3月26日，五洲医疗今日收盘27.26元，上涨3.41%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到45.71倍，总市值18.54亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均45.14倍，行业中值31.99倍，五洲医疗排 名第87位。 股东方面，截至2025年3月10日，五洲医疗股东户数6536户，较上次增加139户，户均持股市值35.28万 元，户均持股数量2.76万股。 安徽宏宇五洲医疗器械股份有限公司的主营业务为一次性使用无菌输注类医疗器械的研发、生产和销 售，以及其他诊断护理等相关医疗用品的集成供应。公司主要产品有注射器、输液输血器、医用穿刺 针、其他诊断和临床护理产品四个系列。公司已经获得国家高新技术企业、安徽省企业技术中心、安徽 省省级工业设计中心等认定，并建立了完善的质量管理体系，且已获得了德国南德意志集团 (TüVSüD)ISO13485:2016医疗器械质量管理体系认证、欧盟CE产品认证、美国FDA企业注册和产品列 名。 最新一期业绩显示，2024年三季报，公司实现营业收入3.43 ...